Latest Breaking News On - Fetal ductus arteriosus - Page 1 : comparemela.com

IBSA Reacquires Commercial Rights to the Flector® Brand in the US Developer of Flector Adds to Portfolio of Topical Pain Therapies News provided by Share this article Share this article PARSIPPANY, N.J., Jan. 12, 2021 /PRNewswire/  IBSA Pharma Inc. has taken back marketing and distribution rights for Flector (diclofenac epolamine) topical system 1.3% from Pfizer as of January 1 st, 2021. With the return of the commercial rights of Flector, a product that IBSA has developed, IBSA now offers two prescription topical drugs to treat acute pain due to minor strains, sprains, and contusions. Both Flector and Licart are manufactured under strict IBSA Quality System control. In 2020, IBSA introduced Licart (diclofenac epolamine) topical system 1.3%, the only FDA-approved once-a-day topical NSAID therapy with next- generation patch technology.

Aldo donatiLicart direct programPharma incNext generation topicalNow availableLicart copay cardAcute painMinor strainsPackage insertCurr med resAthletic trainingFull prescribing informationAsthma relatedAspirin sensitivitySkin reactionsDiscontinue flector